Polaryx Therapeutics, a late-stage clinical biotech company based in Paramus, has announced the appointment of Dr. Eddy Zhu as chief medical officer. Dr. Zhu brings extensive experience in commercial manufacturing, pharmaceutical development, and regulatory approvals, with a strong track record in technical R&D excellence.
“We are excited to have Eddy join Polaryx Therapeutics as our new Chief CMC Officer,” said Alex Yang, J.D., LL.M., chair, and CEO at Polaryx. “Eddy’s expertise in commercial manufacturing and pharmaceutical development will be invaluable as we advance the clinical development of our lead candidate, PLX-200, towards the initiation of our basket trial.”
Dr. Zhu previously served as the product development lead at Sanofi and held senior positions at WuXi AppTec, specializing in drug formulation and development across multiple therapeutic areas. He holds a Ph.D. in Applied Biological Sciences from Ghent University, a master’s degree in food technology from K.U. Leuven and Ghent University, and a PMP certification from the Project Management Institute.
“I am honored to join the Polaryx team and lead the development and implementation of CMC strategies,” said Dr. Zhu. “I look forward to contributing to the acceleration of Polaryx’s pipeline and bringing safe and effective therapies to patients with lysosomal storage disorders.”
Lysosomal storage disorders (LSDs) are a group of rare inherited metabolic diseases caused by enzyme deficiencies, leading to toxic material accumulation in the body. LSDs affect an estimated one in 5,000 live births, with limited treatment options currently available.
